Related Experiment Video
Updated: May 15, 2025
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Peripheral blood cell profile and monocyte-high-density lipoprotein ratio in Alzheimer's disease: a hospital-based
Husniye A Dikbas1, Demet Seker1, Oguz Dikbas2
1Department of Neurology, Giresun University, Giresun, Turkey.
Introduction:
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive decline in memory and cognitive abilities. The monocyte/HDL-C ratio (MHR) has emerged as a new marker of inflammation in recent years. The purpose of this research was to examine MHR alterations in AD and to assess its feasibility as a straightforward and easily computable biomarker for evaluating the severity of the disease.
Material And Methods:
A retrospective case-control study was conducted with 101 patients with AD and 81 age and sex-matched controls from the hospital records. AD was diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. The hospital's electronic patient record data between September 2021 and April 2022 were screened.
Results:
Individuals diagnosed as having AD were classified into three subgroups based on the progression of the disease: mild, moderate, and severe. MHR was higher in the moderate and severe dementia subgroups compared with the controls according to subgroup analysis (p = 0.013). An increase in MHR was found in patients with AD. The multivariate logistic regression analysis model revealed that a one-unit increase in MHR resulted in a 1.081-fold increase in the risk of AD (OR = 1.081, 95% CI: [1.005-1.162]; p = 0.035).
Conclusions:
High MHR values could not be used as a diagnostic test for AD. Instead, because it negatively correlates with MMSE, it could be a good index reflecting increased AD risk and disease severity.
Insights
The monocyte/HDL-C ratio (MHR) is elevated in Alzheimer's disease (AD) patients, particularly those with moderate to severe dementia. While not a diagnostic tool, MHR may indicate increased AD risk and disease severity.
Area of Science:
- Neuroscience
- Biomarkers
- Inflammation
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder impacting memory and cognition.
- The monocyte/HDL-C ratio (MHR) is an emerging inflammatory marker.
- Investigating MHR in AD could reveal a novel biomarker for disease severity.
Purpose of the Study:
- To investigate alterations in the monocyte/HDL-C ratio (MHR) in Alzheimer's disease (AD) patients.
- To evaluate MHR as a potential biomarker for assessing AD severity.
Main Methods:
- Retrospective case-control study involving 101 AD patients and 81 controls.
- AD diagnosis based on NINCDS-ADRDA criteria.
- Analysis of electronic patient records from September 2021 to April 2022.
Main Results:
- MHR was significantly higher in moderate and severe AD subgroups compared to controls (p=0.013).
- Increased MHR was observed in AD patients.
- A one-unit increase in MHR correlated with a 1.081-fold increase in AD risk (OR=1.081, p=0.035).
Conclusions:
- Elevated MHR is associated with increased Alzheimer's disease risk and severity.
- MHR negatively correlates with the Mini-Mental State Examination (MMSE) score.
- MHR may serve as an indicator of AD risk and disease progression, but not a standalone diagnostic test.
More Related Videos
09:41Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
Published on: October 17, 2017
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
